Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amisulpride

FDA-approved product (solution, intravenous), marketed as Barhemsys.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Amisulpride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzamides
FDA pharmacologic class
Dopamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amisulpride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amisulpride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)

    NCT03510325 · start 2019-02-12

    Registered record
    Registry ID
    NCT03510325
    Conditions
    Schizophrenia
    Interventions
    Phase 1: Olanzapine; Phase 1: Risperidone; Phase 1: Amisulpride; Phase 1: Aripiprazole; Phase 1: Perphenazine; Phase 2: Olanzapine; Phase 2: Amisulpride; Phase 2: Clozapine; Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapy; Phase 3B: Clozapine or another SGAs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-02-12
    Completion
    2023-09-27
    Enrolment
    762

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPhase 1: Olanzapine; Phase 1: Risperidone; Phase 1: Amisulpride; Phase 1: Aripiprazole +6 more
    PhasePhase 3
    Registry statusCompleted

  • [18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis

    NCT02880995 · start 2017-11-01

    Registered record
    Registry ID
    NCT02880995
    Conditions
    Schizophrenia
    Interventions
    PET scan; clinical scale; 6 weeks of treatment with amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-11-01
    Completion
    2019-12
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPET scan; clinical scale; 6 weeks of treatment with amisulpride
    PhaseNot applicable
    Registry statusUnknown

  • Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia

    NCT03802838 · start 2017-10-01

    Registered record
    Registry ID
    NCT03802838
    Conditions
    Schizophrenia
    Interventions
    acupuncture; Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-10-01
    Completion
    2019-09-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionacupuncture; Amisulpride
    PhasePhase 4
    Registry statusUnknown

  • Enhancing Recovery in Early Schizophrenia

    NCT02926859 · start 2017-04-08

    Registered record
    Registry ID
    NCT02926859
    Conditions
    Schizophrenia
    Interventions
    Cannabidiol as add-on; Placebo as add-on
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-04-08
    Completion
    2027-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCannabidiol as add-on; Placebo as add-on
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of APD421 as PONV Treatment (Prior Prophylaxis)

    NCT02646566 · start 2016-03

    Registered record
    Registry ID
    NCT02646566
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    APD421; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03
    Completion
    2017-01
    Enrolment
    705

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAPD421; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

    NCT02337062 · start 2015-02

    Registered record
    Registry ID
    NCT02337062
    Conditions
    PONV
    Interventions
    APD421; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-09
    Enrolment
    1,147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPONV
    InterventionAPD421; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity

    NCT02557984 · start 2014-02

    Registered record
    Registry ID
    NCT02557984
    Conditions
    Addiction
    Interventions
    Placebo; Amisulpride; Naltrexone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-04
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAddiction
    InterventionPlacebo; Amisulpride; Naltrexone
    PhaseNot applicable
    Registry statusCompleted

  • Association of Amisulpride Response in Schizophrenia With Brain Image

    NCT02095938 · start 2014-01

    Registered record
    Registry ID
    NCT02095938
    Conditions
    Schizophrenia; Schizophreniform Disorder
    Interventions
    amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2015-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophreniform Disorder
    Interventionamisulpride
    PhasePhase 4
    Registry statusUnknown

  • Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

    NCT01857232 · start 2013-10

    Registered record
    Registry ID
    NCT01857232
    Conditions
    CINV
    Interventions
    Ondansetron; Placebo; Dexamethasone; Fosaprepitant; APD403 IV; APD403 oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2015-02
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCINV
    InterventionOndansetron; Placebo; Dexamethasone; Fosaprepitant +2 more
    PhasePhase 2
    Registry statusCompleted

  • An Investigation of Early Life Stress and Depression

    NCT01701258 · start 2013-08

    Registered record
    Registry ID
    NCT01701258
    Conditions
    Major Depressive Disorder (MDD); History of Childhood Sexual Abuse (CSA)
    Interventions
    Amisulpride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2017-05
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD); History of Childhood Sexual Abuse (CSA)
    InterventionAmisulpride; Placebo
    PhasePhase 1
    Registry statusCompleted

  • European Phase III Study of APD421 in PONV

    NCT01991821 · start 2013-07

    Registered record
    Registry ID
    NCT01991821
    Conditions
    PONV
    Interventions
    APD421; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-01
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPONV
    InterventionAPD421; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    NCT01498770 · start 2013-04-01

    Registered record
    Registry ID
    NCT01498770
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Aripiprazole; Quetiapine; Risperidone; Olanzapine; Ziprasidone; Iloperidone; Paliperidone; Lurasidone; Clozapine; Amisulpride; Sertindole; Zotepine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04-01
    Completion
    2017-12-21
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Aripiprazole; Quetiapine; Risperidone +9 more
    PhaseNot recorded
    Registry statusCompleted

  • Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

    NCT02051387 · start 2013-01

    Registered record
    Registry ID
    NCT02051387
    Conditions
    Schizophrenia
    Interventions
    Cannabidiol CR; Cannabidiol; Amisulpride; Olanzapine; Quetiapine; Risperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2017-08
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCannabidiol CR; Cannabidiol; Amisulpride; Olanzapine +3 more
    PhasePhase 1
    Registry statusCompleted